Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 118Myelodysplastic Syndromes 37Hodgkin Disease 35Leukemia, Myeloid, Acute 33Lymphoma 31Lymphoma, Non-Hodgkin 30Neoplasms, Plasma Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Myeloproliferative Disorders 19Hematologic Neoplasms 18Primary Myelofibrosis 17Recurrence 12Anemia, Aplastic 12Lymphoma, Follicular 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Lymphoma, B-Cell, Marginal Zone 9Hematologic Diseases 9Burkitt Lymphoma 9Leukemia, Prolymphocytic 8Leukemia, Plasma Cell 8Leukemia, Myelomonocytic, Chronic 8Anemia, Refractory, with Excess of Blasts 6Polycythemia Vera 4Ovarian Neoplasms 4Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3

Interventions

keyhole-limpet hemocyanin 1fludarabine phosphate 1fludarabine 1Tetanus Toxoid 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × fludarabine × Plasma cell × Clear all
NCT05092451 2026-05-06

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Germ Cell and Embryonal, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡